Rapport Therapeutics: $150 Million Raised To Utilize The Science Of Receptor-Associated Proteins To Advance Precision Neuromedicines
By Amit Chowdhry ● Sep 6, 2023
Rapport Therapeutics - a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines - recently announced that it has raised $150 million in Series B funding. Led by Cormorant Asset Management, the round includes investments from Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., and all existing investors, which include Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).